Clomipramine is primarily used to address the severity and frequency of intrusive thoughts (obsessions) and the accompanying repetitive behaviors (compulsions) characteristic of Obsessive-Compulsive Disorder (OCD). It provides supportive relief in cases where these ritualistic patterns are severe or have been resistant to prior treatment, which contributes to easing the overall symptom load.

Supporting Treatment-Resistant Obsessive-Compulsive Patterns

Clomipramine is commonly used to help manage symptoms that become more disruptive during flare-ups of OCD. It provides support that helps ease the overall symptom burden associated with the core obsessive and compulsive phenomenology, assisting patients with maintaining functional stability.

Easing Severe Anxiety and Recurrent Panic Episodes

This medication is applied in clinical settings that involve acute or unstable symptom patterns, such as debilitating, recurrent panic attacks and severe anxiety, including phobic avoidance (agoraphobia). It may assist in managing the frequency of these spontaneous, overwhelming fear episodes and is relevant when supportive symptom management is appropriate for these intense manifestations.

Management of Specific Chronic Pain Syndromes

Clomipramine is also applied across therapeutic domains involving chronic neurological pain, such as discomfort arising from nerve damage (neuropathic pain). It may assist with easing symptoms related to chronic neurological pain, providing supportive relief for long-standing sensory disturbances, and is applied in scenarios where additional management of discomfort is required.

---

Quick Fact: Relief for Obsessive Thoughts and Compulsions

Eligibility Map: Who can and cannot use Clomipramine — official regulatory information

Eligibility Scope

Classification	Official Regulatory Status
Populations Allowed	Adults and pediatric patients aged 10 years and older for the approved indication.
Use Not Established	Children under 10 years of age.
Contraindicated	Patients with known hypersensitivity to Clomipramine or other TCAs, those in the acute recovery period after a Myocardial Infarction, and those using a Monoamine Oxidase Inhibitor (MAOI) concurrently or within 14 days.

Eligibility-Related Restrictions

The medicine requires conditional use or caution for specific populations:

• Age and Organ Function: Geriatric patients (aged 65 years and older) should start with cautious, low-dose initiation. Patients with severe hepatic or renal impairment require special consideration and monitoring.
• Comorbidities: Use requires caution in individuals with specific cardiovascular conditions (e.g., heart block or arrhythmias), tumors of the adrenal medulla, or hyperthyroidism.
• Pregnancy/Lactation: Safety during pregnancy is not established; use is permitted only if the benefit justifies the risk to the fetus. Clomipramine is present in breast milk, and the decision to continue use must weigh potential risks versus benefits.

Connection to the overall eligibility profile

Regulatory documents define eligibility through a structured profile of absolute contraindications, conditional restrictions, and specific age-related limitations. This formal approach prohibits use in populations with high-risk conditions and limits use in groups lacking sufficient safety data, thereby establishing the official boundaries for the approved patient population.

The regulatory profile for Clomipramine identifies several classes of clinically significant interactions. The co-administration of Clomipramine with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated across all major governmental drug labels, including agents like Linezolid and Intravenous Methylene Blue, due to the high documented risk of Serotonin Syndrome. This prohibition requires a mandatory 14-day separation period when transitioning therapy between Clomipramine and psychiatric MAOIs.

Pharmacokinetic interactions are documented via the liver enzyme system. Co-administration with potent inhibitors of CYP2D6, CYP1A2, or CYP2C19 (e.g., Fluvoxamine) is noted to increase the plasma concentrations of Clomipramine, potentially leading to systemic overexposure. Conversely, substances like Tobacco/Nicotine can reduce drug exposure by inducing metabolic enzymes.

Official documents also detail significant pharmacodynamic interactions. The risk of Serotonin Syndrome is increased when combining Clomipramine with other serotonergic agents (e.g., Triptans, St. John's Wort). Furthermore, combinations with Pimozide and Thioridazine are contraindicated due to the additive risk of QTc interval prolongation and subsequent severe cardiac risk. The use of alcohol or other CNS Depressants also results in a documented additive effect on the central nervous system.

Clomipramine, a tertiary amine tricyclic, is highly lipophilic and readily crosses the blood-brain barrier, leading to selective accumulation in the central nervous system. Its primary mechanism involves acting as an inhibitor of the serotonin transporter (SERT), blocking the reuptake of 5-hydroxytryptamine (5-HT) into the presynaptic terminal. This initial action rapidly increases the concentration of 5-HT within the synaptic cleft.

The active metabolite, desmethylclomipramine, contributes by inhibiting the reuptake of norepinephrine (NE) via the norepinephrine transporter (NET), further modulating monoaminergic signaling. Clomipramine also acts as an antagonist at several other receptors, including histamine H1, muscarinic cholinergic (M1), and alpha1-adrenergic receptors.

Chronic occupancy of the SERT leads to delayed downstream cascades, involving compensatory changes such as desensitization and down-regulation of certain postsynaptic receptors, particularly the 5-HT2A receptor. These intracellular signaling modifications, including potential impacts on the autophagic flux in neurons, lead to long-term system-level physiological modulation of neural circuits implicated in emotion, stress, and behavioral regulation.

How to Use Clomipramine: Official Administration Guidelines

Clomipramine is administered via the oral route, primarily available as capsules or tablets in strengths such as 25 mg, 50 mg, and 75 mg. The official use of the medicine follows a strict titration protocol designed to gradually introduce the compound into the system.

Treatment typically begins with a low starting dose (e.g., 25 mg once daily for adults with Obsessive-Compulsive Disorder) that is then slowly and incrementally increased over several weeks. This titration phase is intended to establish the optimal maintenance dose, which for adults generally ranges from 100 mg to 150 mg per day, up to a maximum recommended dose of 250 mg daily for the main indications.

---

Administration Contexts

Feature	Official Use Instruction
Timing & Food	The medicine is often instructed to be taken with food during the initial phase to mitigate potential gastrointestinal discomfort.
Dosing Schedule	Dosing may transition from divided daily amounts to a single daily dose taken at bedtime to manage potential daytime sedation.
Discontinuation	When stopping therapy, the dose must be gradually reduced (tapered) to avoid potential withdrawal phenomena.

---

Population Adjustments

Specific dose modifications are required for certain patient groups. Older adults typically begin with a lower starting dose (e.g., 10 mg to 25 mg) and have a significantly lower maximum recommended dose (e.g., 75 mg to 100 mg daily) due to altered metabolism. Similarly, a specific low-dose regimen and a lower maximum dose apply to pediatric patients (aged 10 years and older) being treated for Obsessive-Compulsive Disorder.

Research Evidence / Overview of Studies for Clomipramine

Evidence for Use in Obsessive-Compulsive Disorder (OCD) Studies

Research examining Clomipramine's use in Obsessive-Compulsive Disorder (OCD) has been reported in numerous studies. This evidence comes from Randomized Controlled Trials (RCTs), comparing the compound against placebo or other active medications, along with large-scale Meta-analyses. Researchers examined changes in measured symptoms—like intrusive thoughts (obsessions) and repetitive behaviors (compulsions)—during short-term periods, typically 4 to 12 weeks. They used standardized scales, such as the Y-BOCS, to measure changes in symptom intensity.

The research describes patterns of symptoms observed in the populations during the study period. Long-term data monitored the frequency of symptom return (relapse) and evaluated symptom status (e.g., remission rates) over observation periods extending to a year and sometimes five years or longer. However, research does not fully characterize all potential outcomes for patients who maintain long-term symptom status over many years.

---

Evidence for Use in Severe Anxiety and Recurrent Panic Episode Research

The research relevant to Clomipramine's use in severe anxiety and recurrent panic episodes consists primarily of Clinical Trials and Reviews. These studies were observed in research contexts involving fluctuating or unstable symptoms related to panic disorder. Researchers specifically examined changes in the measured frequency and perceived severity of panic attacks, and they also tracked overall scores on general anxiety scales.

The core evidence base for this application is long-standing, meaning recent comparative evidence against contemporary anti-anxiety treatments is often lacking. Consequently, existing studies provide limited insight into the long-term persistence of observations beyond the studied observation periods. The research volume here is considered Moderate, reflecting its studied background.

---

Evidence for Use in Chronic Neuropathic Pain Syndrome Investigations

Clomipramine was studied for various applications involving chronic neurological pain, including discomfort arising from nerve damage (neuropathic pain). The structure of this evidence includes Randomized Controlled Trials (RCTs) focused on specific pain conditions and Systematic Reviews. Researchers measured outcomes related to physical discomfort, specifically tracking measured change in pain intensity and evaluating outcomes reflecting daily functioning.

Key Studies & References

1. Clomipramine: Obsessive-Compulsive Disorder and General Pharmacological Classification (NIH/NLM Review)
2. World Health Organization (WHO) Essential Medicines List (Inclusion for Psychiatric Disorders)

Common questions about Clomipramine (FAQ)

Q: Does Clomipramine make you sleepy, and can I drive while taking it?

Official product information indicates that side effects like dizziness or drowsiness have been reported during clinical studies. Regulatory precautions associated with the medication include warnings against driving or operating heavy machinery until the effect of the medicine on the individual is known. Concerns regarding these effects should be reviewed with a healthcare professional.

Q: Can children 2 years old use Clomipramine?

The approved prescribing information does not list an indication for the use of Clomipramine in children under a specific age, such as 6 years old. Official labeling defines the patient populations for whom the medicine is intended and safe. Based on this, Clomipramine is not indicated for use in children younger than the approved age range.

Q: Can I drink alcohol while taking Clomipramine?

Regulatory documents indicate that the consumption of alcohol should be avoided or strictly limited while taking this medicine. Alcohol can increase the risk of specific side effects, particularly central nervous system effects such as increased drowsiness. Mixing them could potentially intensify these reactions.

Q: How should I store Clomipramine?

According to the official product information, Clomipramine should be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). Storage directions specify that the product should remain in its original container to protect it from moisture and excessive heat.

How to Store and Dispose of Clomipramine

Clomipramine must be stored according to official regulatory labeling to ensure its stability and effectiveness. The medicine requires storage at Controlled Room Temperature, specifically defined as 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and kept in a tight, light-resistant container that utilizes a child-resistant closure.

Handling and Disposal

The medicine should be kept out of the sight and reach of children and must be protected from freezing. For disposal, unused or expired Clomipramine must not be thrown into household rubbish or wastewater. Patients are required to ask a healthcare professional or pharmacist how to properly dispose of the medicine in accordance with local regulatory requirements.